Faisal Khashid's questions to Kyverna Therapeutics Inc (KYTX) leadership • Q3 2024
Question
Faisal Khashid asked about the company's early thoughts on potential partnerships for the STAT6 degrader program (KT61).
Answer
Founder, President, and CEO Nellie Monofi stated that the company is not currently considering partnerships for KT61. She affirmed that Chimera believes it is best positioned to advance the program through Phase 2B development internally and will only evaluate options as it approaches Phase 3.